Slide 1: Understanding the Value of OCX's Strategic Investments
Understanding the Value of OCX’s Strategic Investments Business Update and 2022 Outlook December 2021 ONCOCYTE LIVES
Slide 2: Forward Looking Statements
Forward Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include, am
Slide 3: Oncocyte's Determa Platform Strategy
Oncocyte’s Determa Platform Strategy Products Deliver Critical Information Throughout the Patient Journey Improving Outcomes and Reducing Costs Treatment Decision Patient Monitoring Should I give Should I give Should I give Is the therapy Is the cancer adjuvant chemo? targeted therapy? immunotherapy
Slide 4: The Emerging Patient Management Paradigm
The Emerging Patient Management Paradigm Transforming a deadly disease to a chronic disorder Adjuvant Therapy Selection Targeted/ Immunotherapy Resistance Selection Targeting ho} ial c oO z Therapeutic a Response ov Monitoring DL oO oO 1 a _ Minimal Residual Molecular Disease Remission BASELINE = ——
Slide 5: Treatment Decision Menu Offers "One Lab" Solution
Treatment Decision Menu Offers “One Lab” Solution Should I give Should I give Should I give lel adjuvant chemo? targeted therapy? immunotherapy? Ocx Treatment Decision Menu ¢ Answers all key treatment decisions treatment ¢ Conserves precious tissue Selection ¢ Two Proprietary Precision Tests ¢ Indus
Slide 6: Patient Monitoring Improves Patient Outcomes
Patient Monitoring Improves Patient Outcomes Patient Monitoring Menu Answers two major questions with unique applications *Is the therapy working? *Is the Cancer Coming Back? Blood-Only applications do not require precious tumor tissue or expensive comprehensive mutational panel Vital CNI results de
Slide 7: Oncocyte 2022 Success Milestones
Oncocyte 2022 Success Milestones Market-focused initiatives to support clinical utility and oncologist adoption ¢ Full market launch of DetermalO/Tx ¢ I0 submission to CMS * Continue I0 clinical studies « Close agreement with global platform Co. ¢ Initiate IVD 10 development Drive « Tx submission to
Slide 8: Transplant Opportunity
Transplant Opportunity TheraSure™ Transplant-MONITOR “ONCOCYTE Where Tomorrow LIVES
Slide 9: Transplant Monitoring Test Will Significantly Expand OCX's Revenue Opportunity
Transplant Monitoring Test Will Significantly Expand OCX’s Revenue Opportunity Transplants by the numbers ~39,000! patients per year (US) * Biomarkers needed to achieve personalized 316,000 living recipients immunosuppression and reduce premature graft loss ~41,0002 patients per year (EU) * Conventi
Slide 10: Oncocyte's Value Creation Roadmap
Oncocyte's Value Creation Roadmap to Kits 2022-2024 Introduce Build Market Establish Transition Oncocyte to in Liver... Transplant Accounts Add Heart and Kidney Center Partnerships Transplant Market 2022 Lab Developed Tests (LDT) Decentralization Oncocyte Generates Revenue Centers Generate Revenue °
Slide 11: TheraSure Transplant Very Well Published
TheraSure™ Transplant Very Well Published Absolute Quantification and dPCR platform patents allows for market differentiation THERAPEUTIC. DRUG MOTORING TheraSure™ Transplant was validated in large clinical studies with: 119 Liver recipients (PLOS Med. ‘17) 345 Kidney recipients (Am J Transplant ‘19
Slide 12: Transplant Go-To Market Strategy Rapidly Delivers New Revenue Streams
Transplant Go-To Market Strategy Rapidly Delivers New Revenue Streams and Prepares Market for Democratization EU Launch Regulated Kit + Launch with lab partners Amedes for No. EU + Sign Agreement with platform partner 1H22 and TBD for Southern EU 1H22 + Engage Clinical Trial sites - 1H22 ¢ File for
Slide 13: OCX 2022 Outlook
OCX 2022 OUTLOOK ONCOCYTE
Slide 14: Product Development Timeline
Product Development Timeline 2022 Represents a Year of Product Launches and Reimbursement Submissions Market Reimbursement z= Clinical CLIA LDT Development Dossier Reimbursement D Validation Launch Initiated Submission Granted By CMS Revenue Stage ~ © + DETERMAS” Px {e) i By End of gS ————>——————_>
Slide 15: Product Launches Over Next 12-18 Months will Drive Revenue Growth and Market Value
Product Launches Over Next 12-18 Months will Drive Revenue Growth and Market Value China Clinical Product Launch DETERMAS” | US Reimbursement | DETERMAD’ | 1H 2022 | 2H2022 | 1H2023 | 2H2023 | 1H2024 | 2H2024 | | DETERMAB, DETERMAS US Reimbursement for Kidney and Heart . “ONCOCYTE US Reimbursement
Slide 16: OCX Is Poised To Deliver on its Portfolio Promise!
OCX Is Poised To Deliver on its Portfolio Promise! 2019/2020 Acquired technology to Launched DetermaRx, Drive market demand for Drive revenue growth expand portfolio to continued product portfolio, expand indications, across all products, minimize risk of development of portfolio, submit for reimbur
Slide 17: Thank You
Thank You ONCOCYTE Investor Contact: Mitch Levine Chief Financial Officer IR@oncocyte.com IR 0507 0920